|
|
Type of Company:
Type:
|
Company
|
Ownership: |
Publicly Traded |
Company Size: |
20 Employees In BC (20 Total)
20 In BC (20 Total)
|
Year Founded: |
1967 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
replicel, biotech, hair, hair loss, implantation
|
Profile Views: |
1,145 Company Profile Views |
|
|
|
RepliCel Life Sciences Inc. is developing a scientific technology that has the potential to become the world's first, minimally invasive, permanent solution for hair loss in men and women.
Using autologous cell implantation technology, dermal sheath cup cells are taken from a patient's own healthy hair follicles and are replicated into the millions over a three month period. These cells are reintroduced into areas of hair loss and the anticipated result is the development of new hair follicles. The procedure has been in development over the past nine years by the company's research scientists and medical experts, and is currently undergoing phase I/IIa clinical trials in Europe. |
|
|
Date |
Type |
Amount |
Investors |
Nov 15, 2020 |
Unattributed |
$2.7 Million CAD |
|
Feb 22, 2021 |
Private Placement |
$2.7 Million CAD |
|
Date |
Type |
Amount |
Investors |
Nov 15, 2020 |
Unattributed |
$2.7M CAD |
|
Feb 22, 2021 |
Private Placement |
$2.7M CAD |
|
|
|
|
Want More RepliCel Life Sciences Inc. News? 1 2 3 4
|
Next »
|
|
|
|
|
|
|
Jul 14, 2021
|
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
|
|
Jun 14, 2021
|
Vancouver-based Cell Therapy Company RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
|
|
Jun 2, 2021
|
Vancouver-based RepliCel Launches Testing of Dermal Injector Units
|
|
May 28, 2021
|
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
|
|
May 21, 2021
|
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map
|
|
May 17, 2021
|
RepliCel Announces Granting and/or Allowance of Seven New Patent Applications
|
|
Feb 23, 2021
|
RepliCel Closes First Tranche of $2.7 Million Strategic Investment Commitment
|
|
Feb 10, 2021
|
RepliCel CEO Provides Corporate Update
|
|
Feb 1, 2021
|
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
|
|
Nov 17, 2020
|
RepliCel Announces a Binding Term Sheet For $2.7 Million Strategic Investment and U.S. Partnership
|
|
|
1 - 10 of 37 results
|
|
 |
|
|
|
Share This Company Profile |
|
|
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
